For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
13
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      326
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy.

          Findings

          The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG). BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules.

          Interpretation

          BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12943-023-01808-9.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

          Naiyer A Rizvi, Matthew Hellmann, Alexandra Snyder … (2015)
          Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was associated with improved objective response, durable clinical benefit, and progression-free survival. Efficacy also correlated with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; each factor was also associated with mutation burden. In one responder, neoantigen-specific CD8+ T cell responses paralleled tumor regression, suggesting that anti-PD-1 therapy enhances neoantigen-specific T cell reactivity. Our results suggest that the genomic landscape of lung cancers shapes response to anti-PD-1 therapy. Copyright © 2015, American Association for the Advancement of Science.
          Article 0 comments Cited 1998 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications

            Yuxin Lin, Jianxin Xu, Huiyin Lan (2019)
            Tumor metastasis is a major contributor to the death of cancer patients. It is driven not only by the intrinsic alterations in tumor cells, but also by the implicated cross-talk between cancer cells and their altered microenvironment components. Tumor-associated macrophages (TAMs) are the key cells that create an immunosuppressive tumor microenvironment (TME) by producing cytokines, chemokines, growth factors, and triggering the inhibitory immune checkpoint proteins release in T cells. In doing so, TAMs exhibit important functions in facilitating a metastatic cascade of cancer cells and, meanwhile, provide multiple targets of certain checkpoint blockade immunotherapies for opposing tumor progression. In this article, we summarize the regulating networks of TAM polarization and the mechanisms underlying TAM-facilitated metastasis. Based on the overview of current experimental evidence dissecting the critical roles of TAMs in tumor metastasis, we discuss and prospect the potential applications of TAM-focused therapeutic strategies in clinical cancer treatment at present and in the future.
            Article 0 comments Cited 505 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Mast Cell Function

              Elaine Zayas Marcelino da Silva, Maria Jamur, Constance Oliver (2014)
              Since first described by Paul Ehrlich in 1878, mast cells have been mostly viewed as effectors of allergy. It has been only in the past two decades that mast cells have gained recognition for their involvement in other physiological and pathological processes. Mast cells have a widespread distribution and are found predominantly at the interface between the host and the external environment. Mast cell maturation, phenotype and function are a direct consequence of the local microenvironment and have a marked influence on their ability to specifically recognize and respond to various stimuli through the release of an array of biologically active mediators. These features enable mast cells to act as both first responders in harmful situations as well as to respond to changes in their environment by communicating with a variety of other cells implicated in physiological and immunological responses. Therefore, the critical role of mast cells in both innate and adaptive immunity, including immune tolerance, has gained increased prominence. Conversely, mast cell dysfunction has pointed to these cells as the main offenders in several chronic allergic/inflammatory disorders, cancer and autoimmune diseases. This review summarizes the current knowledge of mast cell function in both normal and pathological conditions with regards to their regulation, phenotype and role.
              Article 0 comments Cited 193 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Qin Yu: 4003200105@hmc.edu.cn
                Wenhao Fu: 1206200317@hmc.edu.cn
                Yutang Fu: 1207200128@hmc.edu.cn
                Wenjing Ye: 0309190311@hmc.edu.cn
                Huiqiong Yan: 881012021060@hmc.edu.cn
                Furong Tang: furong.tang@hotmail.com
                Fangwei Dai: fangweidai@163.com
                Wei Han: hanwei3612@163.com
                Journal
                Journal ID (nlm-ta): Mol Cancer
                Journal ID (iso-abbrev): Mol Cancer
                Title: Molecular Cancer
                Publisher: BioMed Central (London )
                ISSN (Electronic): 1476-4598
                Publication date (Electronic): 30 August 2023
                Publication date PMC-release: 30 August 2023
                Publication date Collection: 2023
                Volume: 22
                Electronic Location Identifier: 143
                Affiliations
                [1 ]GRID grid.506977.a, ISNI 0000 0004 1757 7957, School of Information Engineering, , Hangzhou Medical College, ; Hangzhou, Zhejiang China
                [2 ]GRID grid.506977.a, ISNI 0000 0004 1757 7957, School of Medical Imaging, , Hangzhou Medical College, ; Hangzhou, Zhejiang China
                [3 ]GRID grid.506977.a, ISNI 0000 0004 1757 7957, Center of Laboratory Animal, , Hangzhou Medical College, ; Hangzhou, 310013 Zhejiang China
                [4 ]GRID grid.506977.a, ISNI 0000 0004 1757 7957, Zhejiang Provincial Key Laboratory of Laboratory Animals and Safety Research, , Hangzhou Medical College, ; Hangzhou, 310013 Zhejiang China
                [5 ]GRID grid.506977.a, ISNI 0000 0004 1757 7957, School of Clinical Medicine, , Hangzhou Medical College, ; Hangzhou, Zhejiang China
                [6 ]GRID grid.506977.a, ISNI 0000 0004 1757 7957, School of Medical Laboratory and Biological Engineering, , Hangzhou Medical College, ; Hangzhou, Zhejiang China
                [7 ]GRID grid.506977.a, ISNI 0000 0004 1757 7957, Engineering Research Center of Novel Vaccine of Zhejiang Province, , Hangzhou Medical College, ; Hangzhou, 310013 Zhejiang China
                [8 ]GRID grid.459520.f, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, ; Quzhou, Zhejiang China
                [9 ]GRID grid.12527.33, ISNI 0000 0001 0662 3178, Department of Basic Medical Sciences, School of Medicine, , Tsinghua University, ; Beijing, China
                Article
                Publisher ID: 1808
                DOI: 10.1186/s12943-023-01808-9
                PMC ID: 10466744
                PubMed ID: 37649051
                SO-VID: 94ecb463-84ed-4b3b-8b0d-eeed7f6b7090
                Copyright © © BioMed Central Ltd., part of Springer Nature 2023
                License:

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                Date received : 23 May 2023
                Date accepted : 17 June 2023
                Funding
                Funded by: National Innovation and Entrepreneurship Training Program for College Students
                Award ID: 202013023018, 202313023030
                Award ID: 202013023018, 202313023030
                Award ID: 202013023018, 202313023030
                Award ID: 202013023018, 202313023030
                Funded by: National Natural Science Foundation of China
                Award ID: 62271353, 62001311
                Funded by: Natural Science Foundation of Sichuan Province
                Award ID: 2022NSFSC0926
                Funded by: FundRef http://dx.doi.org/10.13039/501100017594, Medical Science and Technology Project of Zhejiang Province;
                Award ID: 2018KY351, 2020KY530
                Award ID: 2018KY351, 2020KY530
                Funded by: Hangzhou Medical College Institute Special Project
                Award ID: YS2021009
                Funded by: Department of Education of Zhejiang Province
                Award ID: Y201942573
                Funded by: FundRef http://dx.doi.org/10.13039/501100012175, Zhejiang Traditional Chinese Medicine Administration;
                Award ID: 2021ZB081
                Funded by: The Natural Science Foundation of Zhejiang Province
                Award ID: LXZ22H300001
                Categories
                Subject: Correspondence
                Custom metadata
                issue-copyright-statement © BioMed Central Ltd., part of Springer Nature 2023

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: bnip3,immune infiltration,pan-cancer analysis,prognostic biomarker,diagnosis
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: bnip3, immune infiltration, pan-cancer analysis, prognostic biomarker, diagnosis

                Comments

                Comment on this article

                scite_

                Similar content326

                See all similar

                Cited by1

                See all cited by

                Most referenced authors268

                See all reference authors